Deanna Angello Email & Phone Number

Mclean, Virginia, Us

Recruited to company with a charter to provide mentorship to Seed to Series A company CEOs and to serve as an acting Chief Commercial Officer providing business strategy guidance to preclinical, clinical, and early-stage healthcare companies on about clinical development, navigating the healthcare ecosystem, scaling the business, and growth strategies. Accountable for designing and implementing a comprehensive accelerator program that promotes market readiness and makes introductions to industry contacts across life sciences, biopharma, and investors to facilitate funding opportunities and strategic partnerships for CEOs.Key Accomplishments:● Secured a total of $20 million in seed funding and contracts from angel investors and high net worth individuals.● Generated a 30% increase in investor interest by mentoring over 25 early-stage CEOs and Founders and conducting 40+ one-on-one coaching sessions to refine business strategies.● Developed and executed Go-To-Market (GTM) strategies for 10 pre-revenue (and preclinical) products and technologies, positioning them for successful market entry and future revenue generation.

Mclean, Virginia, Us

San Mateo, Ca, Us

Actively participating in monthly pitch calls and due diligence for potential investments in diseases related to aging and solutions for ensuring greater longevity and health span.Portfolia is the world’s most powerful network of women investing in the companies we want in the world for returns and impact.

Raritan, New Jersey, Us

Recruited by J&J’s President of the $6B Oncology unit to lead the transition from primary care to a specialty-focused customer engagement model, emphasizing Key Account Management and strategic partnerships. Led three product launches across five Commercial functions—Franchise Strategy, Digital/Omnichannel, Patient Services, Key Account Management, and Clinical Nurse Educators. Accountable for driving three of the President’s top five growth initiatives to advance the oncology portfolio and improve patient outcomes. Oversaw a team of 100+ and managed a $35M budget for a portfolio including Darzalex®, Erleada®, Imbruvica®, Rybrevant®, Carvykti®, Tecvayli®, and Balversa®. Key Accomplishments:● Accountable for driving success and share on three new product launches: Rybrevant, Carvykti and Tecvayli. ● 15% increase in product adoption of current commercial products and strengthened partnership with Key Accounts by securing two major pathway wins at leading oncology key accounts. ● Generated a 20% increase in HCP engagement and a 10% boost in sales by executing an innovative omnichannel strategy that included integrated AI marketing and digital transformation.● Improved customer engagement by launching two pilots to establish long-term strategic partnerships with leading cancer centers, hospitals, and oncology networks to expand access and enhance adoption of cutting-edge oncology therapies.

Santa Monica, California, Us

Recruited by the newly hired CEO to lead the development and execution of Kite’s enterprise growth strategy for Yescarta and Tectarus and to establish and lead the governance for the executive team and execution of the CEO priorities and agenda. Accountable for leading a change management charter to support the enterprise growth strategy to deliver a business plan focused on streamlining operations, determining R&D priorities, and delivering on a roadmap for building capabilities to transform from a high growth startup into a sustainable mid-sized biotech. Key Accomplishments:● Worked with the C-suite to streamline decision making, the R&D pipeline priorities and to focus on upskilling this cell therapy organization and its commercialization efforts.● Improved organizational efficiency and identified priorities by creating an Executive Forum for the functional leadership.

South San Francisco, California, Us

assets: Ph III crenezumab and gantenerumab and two PhII assets in clinical trials. Accountable for leading the commercial strategy, value and pricing, market access, business insights and analytics for primary and specialty care markets for two PIII programs which had the potential to be disease-modifying (DM) therapies with $10B in revenue (failed in PhIII). Additional accountabilities for go/no-go decisions in pipeline and business development & licensing for earlier stage assets. Led Alzheimer’s pre-launch market shaping and launch planning. Built the first cross-functional team to create and execute a cohesive strategy for the first AD DM drug. Developed an organizational structure and capabilities launch plan essential for bringing transformative science to market.Key Accomplishments:● Worked closely with the top global neurodegeneration KOLs on market development initiatives to gain alignment on the definition of disease modifying features and benefits. Recognized by senior management for this innovative market development program which is now a best practice for the organization.● Engaged the Payors in developing innovative risk sharing reimbursement strategies that were based on shared risk and patient outcomes for this potentially transformative Alzheimer’s therapy.

South San Francisco, California, Us

Recruited to lead the development of the corporate strategy and market development plan for Genentech’s Oncology portfolio which included: Herceptin, Rituxan, and Avastin which represented over $10B in company revenue – the largest competitive threat in their history. Executed a charter to help the company address the new entry of biosimilars in the US. Accountable for working across the broader Genentech/Roche enterprise to build out the capability of marketing excellence to enable the entire commercial organization to be more competitive in this new landscape for biologics. Led a nimble team of 12.

King Of Prussia, Pa, Us

● Led Marketing Strategy Task Force including the development of a comprehensive strategy defining value proposition and message platform to advance awareness. o Increased Website visitors by 427%; Doubled number of Donations● Selected for Strategic Planning Task Force and led Board through evolved vision, strategic and operational planning and prioritization of initiatives and investments.● Personally raised over $50K for clinical research

New York, New York, Us

Gained extensive industry experience in progressive roles of responsibility, including brand marketing, new product planning, market research and analytics, and business development across multi-billion-dollar brands. Worked in lifecycle management, market development, pre-launch, launch to peri-LOE. Key Accomplishments:● Revitalized $3B product, delivering 10% revenue growth by creating multi-specialists and PCP marketing strategies. Turned around double-digit decline in less than 1 year by collaborating with 5 Regional Presidents and marketers to train 2K commercial staff on customer-centric approach in less than 6 weeks, a 50% decrease in execution time. ● Reinvigorated sales force by developing distinctive message platform including creation of target patient types, resulting in increased SOV over competition and renewed product growth, driving sales 10%.● Delivered 15% market share growth by identifying key insights, leading to significant repositioning in brand strategy and solidifying brand’s competitive advantages.

Mclean, Va, Us

Led engagement that resulted in repeat business. Spearheaded survey development, deployment and analysis as member of NCIS team; findings led to new $400M contract for business process improvement and change initiative● Strengthened internal capacity by with gap analysis of firm’s Commercial and Public Sector consulting arms and integrating sector-independent training courses. Created unified Center of Excellence for Professional Development

Amsterdam, Nl

Supported clients in strategy development, operations, business planning and process improvement.● Key member on pilot for Centers for Disease Control helping firm break into healthcare market securing future work.● Led three analysts in the revision of regulatory and data policies for the Centers for Medicare and Medicaid Services (CMS) web-based Medicare appeals database which lead to 20% improvement in efficiency and processing rate.

Mba, Finance & Strategic Management

Bs, Psychology

Study Aboard, Business Administration And Management, General